Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study

Health Economic Consequences of a Tightly Controlled Dose Reduction Strategy for Adalimumab, Etanercept and Ustekinumab Compared with Standard Psoriasis Care: A Cost-utility Analysis of the CONDOR Study

A dose reduction strategy for adalimumab, etanercept and ustekinumab in patients with psoriasis who have stable and low disease activity has recently been compared with usual care in the CONDOR study (CONtrolled DOse Reduction) of biologics in patients with psoriasis with low disease activity. The a...

Full description

Bibliographic Details
Main Authors: Selma Atalay, Juul M.P.A. van den Reek, Marisol E. Otero, Marcellus D. Njoo, Johannes M. Mommers, Paul M. Ossenkoppele, Marjolein I. Koetsier, Maartje M. Berends, Peter C.M. van de Kerkhof, Hans M.M. Groenewoud, Alfons A. den Broeder, Elke M.G.J. de Jong, Wietske Kievit
Format: Article
Language:English
Published: Society for Publication of Acta Dermato-Venereologica 2020-12-01
Series:Acta Dermato-Venereologica
Subjects:
psoriasis
biologics
condor study
cost-utility
dose reduction strategy
Online Access: https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3692

Internet

https://www.medicaljournals.se/acta/content/html/10.2340/00015555-3692

Similar Items